Aureka Biotechnologies

Biotech · AI/ML · Drug Discovery

Funding

Aureka raises $100M Series B to build AI biological world model

Its closed-loop lab generates fresh experimental data to keep AI models grounded in real biology, not just public databases.

• Aureka Biotechnologies closed a $100 million Series B on Aug. 10, 2026, with Granite Asia exclusively funding the first tranche and an unnamed strategic investor leading the second.
• Founded in 2023, the Laguna Hills, California and Shanghai-based company builds AI-native biological foundation models, including its flagship protein model AuraIDE, to redesign drug discovery end to end.
• The new capital will fund large-scale training of next-generation foundation models and upgrade Aureka's 'Lab-in-the-Loop' platform, which feeds experimental data back into model training.
• The Series B brings Aureka's total funding to nearly $200 million since 2023, following a $35 million Series A+ led by HSG (formerly Sequoia China) in April 2026.
• Unlike models trained solely on static public databases, Aureka's system generates its own experimental data through continuous design-validation-learning cycles meant to reduce bias in predictions.
• The deal underscores investor appetite for 'techbio' firms pairing AI foundation models with wet-lab feedback loops, a hybrid approach also pursued by projects like the Arc Institute's Evo.